ADVAGRAF®
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Liver Transplantation
Conditions
Liver Transplantation
Trial Timeline
Jul 1, 2015 → Dec 14, 2017
NCT ID
NCT04761731About ADVAGRAF®
ADVAGRAF® is a approved stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT04761731. Target conditions include Liver Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Liver Transplantation were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03423225 | Approved | Completed |
| NCT04761731 | Approved | Completed |
| NCT02161237 | Approved | Completed |
Competing Products
20 competing products in Liver Transplantation